NasdaqGS:EXELBiotechs
Exelixis (EXEL) Stock Drops As Guidance Cut Clouds Profit Strength
Exelixis stock just gave investors a jolt. The shares closed down almost 8% at US$52.20, even though the company printed another quarter of solid oncology profits. Q2 revenue came in at about US$628.7 million and net income reached roughly US$212 million, keeping the cabozantinib cash engine firmly running.
The tension for you now is time horizon. Short term traders are reacting to the trimmed full year revenue guidance. Long term holders will be looking at the higher net profit margin and...